Biotinylated Human Her2, His,Avitag (Cat. No. HE2-H82E2) immobilized on SA Chip can bind Herceptin® with an affinity constant of 17 pM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Trastuzumab biosimilar (Biocad) | BCD-022 | Approved | Biocad | Breast cancer | Details | |||||
| Trastuzumab biosimilar (Intas Pharmaceuticals) | Approved | Intas Biopharmaceuticals | Breast cancer | Details | ||||||
| Afatinib Dimaleate | BIBW-2992; BIBW-2992-MA2,BIBW 2992,BIBW2992 | Approved | Boehringer Ingelheim | GILOTRIF | fda | Non small cell lung cancer (NSCLC), Metastatic squamous non-small cell lung cancer (NSCLC) | BOEHRINGER INGELHEIM | 2013-07-12 | Non small cell lung cancer (NSCLC), Metastatic squamous non-small cell lung cancer (NSCLC) | Details |
| Trastuzumab biosimilar (Zydus) | Approved | Zydus cadila | Breast cancer | Details | ||||||
| Trastuzumab | RO45-2317; Anti-HER2/neu-MAb; MKC-454; R-597; RG-597; huMAb4D5-8 | Approved | Genentech, Chugai | HERCEPTIN | fda | Gastric cancer, Breast cancer | GENENTECH | 1998-09-25 | Gastric cancer, Breast cancer | Details |
| Tucatinib | ARRY-380; ONT-380 | Approved | Array BioPharma, Cascadian Therapeutics, Seattle Genetics | TUKYSA | fda | SEATTLE GENETICS | 2020-04-17 | Breast cancer | Details | |
| Trastuzumab/Hyaluronidase-oysk | Approved | Genentech | HERCEPTIN HYLECTA | fda | GENENTECH INC | 2019-02-28 | Metastatic breast cancer | Details | ||
| Trastuzumab biosimilar (Reliance Life Sciences) | R-TPR-016 | Approved | Reliance Life Sciences | Breast cancer | Details | |||||
| Trastuzumab biosimilar (AXXO) | Approved | AXXO | Breast cancer | Details | ||||||
| Trastuzumab biosimilar (Celltrion) | CT-P06; CT-P6,CTP06; CTP6 | Approved | Celltrion, Nippon Kayaku, Teva | trastuzumab | ema | Celltrion Healthcare Hungary Kft. | 2018-02-08 | Gastric cancer, Breast cancer | Details | |
| Trastuzumab biosimilar (Allergan/Amgen) | ABP-980,ABP980; ABP 980 | Approved | Synthon, Allergan, Daiichi Sankyo, Amgen | trastuzumab | ema | Amgen Europe B.V., Breda | 2018-05-16 | Gastric cancer, Breast cancer | Details | |
| Fam-trastuzumab deruxtecan | DS-8201; DS-8201a | Approved | Daiichi Sankyo, Bristol-Myers Squibb, Puma Biotechnology, AstraZeneca | ENHERTU | fda | DAIICHI SANKYO | 2019-12-20 | HER2-positive breast cancer, HER2-positive metastatic breast cancer | Details | |
| Neratinib Maleate | CAN-030; HKI-272; PB-272; PF-0528767; WAY-179272 | Approved | Pfizer, Puma Biotechnology, CANbridge Life Sciences | NERLYNX | fda | HER2-positive metastatic breast cancer | PUMA BIOTECH | 2017-07-17 | HER2-positive metastatic breast cancer | Details |
| Lapatinib Ditosylate Hydrate | GW-572016F; GW-572016; GW-2016,GW572016,GW 572016F,GW572016F,GW 572016 | Approved | GlaxoSmithKline, Novartis | TYKERB | fda | Breast cancer | NOVARTIS | 2007-03-13 | ER positive metastatic breast cancer, HR-negative/HER2-positive metastatic breast cancer, Breast cancer, HER2-positive metastatic breast cancer, HER2-positive advanced breast cancer | Details |
| Trastuzumab biosimilar (Dr. Reddy's Laboratories) | Approved | Dr Reddys Laboratories | Breast cancer | Details | ||||||
| Trastuzumab biosimilar (Biocon/Mylan) | Bmab-200; Myl-1401O; HerMyl-1401O | Approved | Biocon, Mylan | OGIVRI | fda | MYLAN GMBH | 2017-12-01 | Gastric cancer, Breast cancer, Gastroesophageal junction adenocarcinoma | Details | |
| Ado-trastuzumab emtansine | T-DM1; PRO-132365; R-3502; RG-3502; RO-5304020 | Approved | Genentech, Chugai | KADCYLA | fda | Breast cancer | GENENTECH | 2013-02-22 | Breast cancer, HER2-positive metastatic breast cancer | Details |
| Trastuzumab biosimilar (Samsung Bioepis) | SB-3; AMT-901,SB3; AMT901 | Approved | Samsung Bioepis, Merck Sharp & Dohme, C-Bridge Capital Partners | trastuzumab | ema | Samsung Bioepis NL B.V. | 2017-11-15 | Gastric cancer, Breast cancer | Details | |
| Trastuzumab biosimilar (AryoGen Pharmed) | Approved | AryoGen Biopharma | Gastric cancer, Breast cancer | Details | ||||||
| Dacomitinib | PF-00299804; PF-299; PF-299804; PF-804; PF-00299804-03; PF-00299804-3,PF00299804,PF299804,PF299 | Approved | Pfizer, SFJ pharmaceuticals | VIZIMPRO | fda | Non small cell lung cancer (NSCLC) | PFIZER INC | 2018-09-27 | Non small cell lung cancer (NSCLC) | Details |
| Pertuzumab | rhuMab-2C4; R-1273; RG-1273; RO-4368451-F01; RO-4368451 | Approved | Genentech, Chugai | PERJETA | fda | Breast cancer | GENENTECH | 2012-06-08 | Breast cancer, HER2-positive metastatic breast cancer | Details |
| Pyrotinib Maleate | SHR-1258; BLTN; HTI-1001 | Approved | Jiangsu Hengrui Medicine | Pyrotinib Maleate Tablets | cfda | HER2-positive metastatic breast cancer | 2018-08-12 | HER2-positive metastatic breast cancer | Details | |
| Trastuzumab biosimilar (Pfizer) | PF-05280014; PF-5280014,PF05280014; PF5280014 | Approved | Pfizer | trastuzumab | ema | Pfizer Europe MA EEIG | 2018-07-26 | Gastric cancer, Breast cancer | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| IDN-6439 | IDN-6439 | Preclinical | Indena | Head and neck cancer | Details |
| Trastuzumab glyco-optimised (Glycotope) | GT-Mab-7.3-GEX | Phase Ⅰ | Glycotope | Gastric cancer, Breast cancer | Details |
| Anti-HER2 small molecule imaging agent (Affibody) | 68GaABY025; ABY-002; ABY-0125; ABY-025 | Phase Ⅲ | Affibody | Breast cancer | Details |
| AVA-006 | AVA-006 | Phase Not Specified | Avacta Group, Glythera, Avacta Group, Glythera | Cancer | Details |
| Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) | Phase Ⅰ | National Cancer Institute | Solid tumours | Details | |
| ADCT 502 (ADC Therapeutics) | ADCT-502 | Phase Ⅰ | Cancer Research Technology, ADC Therapeutics | Solid tumours | Details |
| Trastuzumab biosimilar (Hualan Biological Engineering) | Phase Ⅲ | Hualan Biological Engineering | Metastatic breast cancer | Details | |
| Trastuzumab biosimilar (BIOCND/Genor Biopharma) | GB-221,GB221 | Phase Ⅲ | Genor Biopharma | Breast cancer | Details |
| Trastuzumab biosimilar (BioIntegrator) | BI-Mab-03 | Phase Ⅰ | BioIntegrator | Breast cancer | Details |
| AU-101 | AU-101 | Phase Ⅱ | Aurora BioPharma | Breast cancer, Osteosarcoma, Glioblastoma | Details |
| RG-6194 | RG-6194; BTRC-4017A | Phase Ⅰ | Roche | Solid tumours | Details |
| Pirotinib Hydrochloride | KBP-5209,KBP5209 | Phase Ⅱ | XuanZhu Pharma | Non small cell lung cancer (NSCLC), Breast cancer, Lung cancer | Details |
| KSP-QRH-E3-IRDye800 | Phase Ⅰ | University of Michigan | Cholangiocarcinoma | Details | |
| HER2p63-71 peptide vaccine (Mie University) | Phase Ⅰ | Mie University | Cancer | Details | |
| MEDI-4276 | MEDI-4276 | Phase Ⅰ | MedImmune | Gastric cancer, Breast cancer | Details |
| RG-6148 | DHES-0815A; RG-6148 | Phase Ⅰ | Roche | HER2-positive breast cancer | Details |
| Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) | Phase Ⅰ | Qilu Pharmaceutical | Breast cancer | Details | |
| Mubritinib | TAK-165,TAK165 | Phase Ⅰ | Takeda | Breast cancer | Details |
| Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical) | HS-022 | Preclinical | Hisun Pharm | Breast cancer | Details |
| Trastuzumab biosimilar (CTTQ Pharma) | Phase Ⅲ | Chiatai Tianqing (CTTQ) | Breast cancer | Details | |
| CP-724714 | CP-724714 | Phase Ⅱ | Pfizer | Metastatic breast cancer | Details |
| 111In-CHxADTPA-trastuzumab (Center for Cancer Research, Leidos Biomedical Research Inc/National Institutes of Health) | Phase Ⅱ | National Institutes of Health | Diagnostic agents | Details | |
| Varlitinib Ditosylate | ARRY-334543; ARRY-543; ASLAN-001; QBT-01; SPS-4370 | Phase Ⅲ | Array BioPharma | Biliary cancer | Details |
| LCB14-0110 | LCB14-0110; FS-1502 | Phase Ⅰ | LegoChemBio, Fosun Pharma | Gastric cancer, Breast cancer, Solid tumours | Details |
| Anti-HER2 ribozyme (Elan/Sirna) | Phase Ⅰ | Elan Pharm, Merck | Breast cancer, Ovarian cancer | Details | |
| Margetuximab | MGAH-22,MGAH22 | BLA Filing | MacroGenics, Green Cross, Zai Lab | Gastric cancer, HER2-positive metastatic breast cancer | Details |
| Trastuzumab biosimilar (Hanwha Biologics) | HD-201 | BLA Filing | Hanwha Biologics, Prestige BioPharma, Mundipharma | Gastric cancer, oesophageal cancer, Breast cancer | Details |
| NJH-395 | NJH-395,NJH 395,NJH395 | Phase Ⅰ | Novartis | Cancer | Details |
| Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase Ⅱ | Shanghai Allist Pharmaceuticals | Breast cancer, Lung cancer | Details |
| PX-1031 (Pharmexa) | PX-1031; PX-103.1; ME-103.1.1; ME-103 | Phase Ⅱ | Pharmexa | Breast cancer | Details |
| trastuzumab biosimilar (Hetero) | Ado-Trastuzumab biosimilar (Hetero) | Phase Ⅲ | Hetero Drugs | Cancer | Details |
| AC-480 | AC-480; BMS-599626 ,AC480; BMS599626 ,AC 480; BMS 599626 | Phase Ⅰ | Ambit biosciences | Glioma, Solid tumours | Details |
| Cancer vaccine (Merck & Co/Vical) | V-930; V-932,V932,V930 | Phase Ⅰ | Merck Sharp & Dohme, Vical | Non small cell lung cancer (NSCLC), Breast cancer, Colorectal cancer, Ovarian cancer | Details |
| MRG-002 | MRG-002 | Phase Ⅰ | Shanghai Miracogen | Gastric cancer, Breast cancer, Solid tumours | Details |
| GB-251 | GB-251,GB251 | Phase Ⅰ | Genor Biopharma | HER2-positive metastatic breast cancer | Details |
| Ertumaxomab | Phase Ⅱ | Trion Pharma, NeoPharm | Breast cancer | Details | |
| HER2.taNK | NK-92/5.28.z | Phase Ⅰ | NantKwest | Glioblastoma | Details |
| CUDC-101 | CUDC-101,CUDC101 | Phase Ⅰ | Curis | Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Hepatocellular carcinoma (HCC), Head and neck cancer | Details |
| HER-2/HER-1 vaccine (Ohio State University) | Phase Ⅰ | Ohio State University | Solid tumours | Details | |
| Recombinant human neuregulin-1 | rhNRG-1 | BLA Filing | Zensun, SciClone | Heart failure, Acute myocardial infarction (AMI) | Details |
| SHR-A1201 | SHR-A1201 | Phase Ⅰ | Jiangsu Hengrui Medicine | HER2-positive metastatic breast cancer | Details |
| Larotinib Mesylate | Z-650 | Phase Ⅱ | HEC Pharm | Esophagus cancer | Details |
| TAK-285 | TAK-285,TAK285 | Phase Ⅰ | Takeda | Solid tumours | Details |
| Trastuzumab/Pertuzumab | RG-6264; RO-7198574 | BLA Filing | Roche | Breast cancer | Details |
| Trastuzumab biosimilar (Bionovis/The Instituto Vital Brazil) | Phase Not Specified | Bionovis, The Instituto Vital Brazil | Gastric cancer, Breast cancer, Metastatic breast cancer | Details | |
| KSP-910638-G | KSP-910638-G; KSP-910638G | Phase Ⅰ | University of Michigan | Gastrointestinal cancer | Details |
| Pertuzumab biosimilar (Shanghai Henlius Biotech) | HLX-11,HLX11 | IND Filing | Shanghai Henlius Biotech | Breast cancer, Metastatic breast cancer | Details |
| Pelitinib | EKB-569; WAY-EKB-569,EKB569,WAY EKB569 | Phase Ⅱ | Pfizer | Non small cell lung cancer (NSCLC), Colorectal neoplasms | Details |
| Iodine-131-SGMIB anti-HER2 monoclonal antibody | 131I-SGMIB-anti-HER2-VHH1; [131I]-SGMIB Anti-HER2-VHH1; CAM-H2; Iodine-131-SGMIB-anti-HER2-VHH1 | Phase Ⅰ | Camel-IDS | Breast cancer | Details |
| Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) | B-003 (Shanghai Pharma) | Phase Ⅰ | Shanghai Pharma, Shanghai Jiaolian | HER2-positive breast cancer | Details |
| Disitamab Vedotin (Shijiazhuang Zhongqi Pharmaceutical) | Phase Ⅰ | Shijiazhuang Zhongqi Pharmaceutical | HER2-positive advanced breast cancer | Details | |
| GBR-1302 | GBR-1302; HBM-9302 | Phase Ⅱ | Glenmark Pharmaceuticals, Harbour BioMed | Breast cancer | Details |
| Trastuzumab biosimilar (NeuClone/Serum Institute of India) | Phase Ⅰ | NeuClone, Serum Institute of India | Gastric cancer, Breast cancer | Details | |
| Sapitinib | AZD-8931 | Phase Ⅱ | AstraZeneca | Colorectal cancer | Details |
| ALT-P7 | HM2-MMAE; ALT-P7 | Phase Ⅰ | Alteogen, 3SBio | Gastric cancer, Breast cancer | Details |
| AE-37/GP-2 vaccine | AE-37 (Generex Biotechnology Corporation) | Phase Ⅱ | Generex Biotechnology Corporation | Prostate cancer, Breast cancer | Details |
| KN-026 | KN-026 | Phase Ⅱ | Alphamab | Gastric cancer, Breast cancer | Details |
| BMS-690514 | BMS-690514,BMS690514 | Phase Ⅱ | Bristol-Myers Squibb | Non small cell lung cancer (NSCLC), Breast cancer | Details |
| 14C-labeled poziotinib | Phase Ⅰ | Spectrum Pharmaceuticals | Solid tumours | Details | |
| A-166 | A-166,A166 | Phase Ⅱ | Kelun Pharmaceutical | Gastric cancer, HER2-positive breast cancer | Details |
| HER2(EQ)BBzeta/CD19 T cells (City of Hope) | Phase Ⅰ | Mustang Bio, City of Hope National Medical Center | Glioma | Details | |
| ADXS-31164 | ADXS31-164; ADXS-31164; ADXS-cHER2; ADXS-HER2 | Phase Ⅱ | University of Pennsylvania, Advaxis | Solid tumours, Osteosarcoma | Details |
| Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) | SIBP-01 | Phase Ⅲ | Shanghai Institute of Biological Products | Breast cancer, Metastatic gastric carcinoma, Metastatic breast cancer | Details |
| GB-235 | GB-235,GB235 | Phase Ⅰ | Genor Biopharma | HER2-positive breast cancer | Details |
| Trastuzumab biosimilar (STC Biologics) | STC-101 | Phase Ⅰ | STC Biologics | Solid tumours | Details |
| MP-412 | AV-412; MP-412,MP412,AV412 | Phase Ⅱ | Mitsubishi Tanabe Pharma | Solid tumours | Details |
| Hemay-022 | Hemay-022 | Phase Ⅰ | Tianjin Hemay Biotech, Xia Jiang Hemay Pharmaceutical | HER2-positive breast cancer | Details |
| Recombinant anti-HER2 antibody (Anke Biotech) | Phase Ⅲ | Anke Biotechnology | Breast cancer | Details | |
| Selatinib Ditosilate | QLNC-120,QLNC120 | Phase Ⅱ | Qilu Pharmaceutical, Qilu Antibiotics (Linyi) Pharmaceutical | Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer | Details |
| Recombinant anti-HER2 antibody-Tub114 | DX126-262; DAC-001 | Phase Ⅰ | Hangzhou DAC Biotech | HER2-positive breast cancer, Solid tumours | Details |
| ICT-140 | ICT-140 | Preclinical | ImmunoCellular Therapeutics | Ovarian cancer | Details |
| AEE-788 | AEE-788; NVP-AEE-788,AEE788,NVPAEE788 | Phase Ⅱ | Novartis | Glioblastoma multiforme | Details |
| TAA-013 | TAA-013,TAA013; TAA 013 | Phase Ⅰ | TOT Biopharm | HER2-positive breast cancer, Solid tumours | Details |
| Anti-CD3-anti-HER2-activated T cells | Phase Ⅱ | TransTarget, Barbara Ann Karmanos Cancer Institute, National Cancer Institute | Breast cancer | Details | |
| Trastuzumab biosimilar (Tanvex Biopharma) | TX-05 | Phase Ⅲ | Tanvex BioPharma | Breast cancer | Details |
| SPH-3261 | SPH-3261 | IND Filing | Shanghai Pharma | Malignancies | Details |
| Anti-HER2 antibody toxin conjugate (TopoTarget) | Phase Ⅰ | Novartis, Topotarget | Cancer | Details | |
| Trastuzumab duocarmazine | SYD-985,SYD985; SYD 985 | Phase Ⅲ | Synthon | Gastric cancer, Breast cancer, Solid tumours | Details |
| ETBX-021 | ETBX-021 | Phase Ⅱ | Etubics Corporation, NantBioScience | Metastatic pancreas cancer | Details |
| [89Zr]-Df-Trastuzumab | Phase Ⅰ | University of Alabama at Birmingham | Breast cancer | Details | |
| Multi-epitope HER2 peptide vaccine (Mayo Clinic) | Phase Ⅰ | Mayo Clinic | Breast cancer | Details | |
| AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase Ⅰ | Arromax Pharmatech | Gastric cancer, HER2-positive breast cancer, Pancreatic cancer | Details |
| TT-16 | TT-16 | Preclinical | Tessa Therapeutics | Head and neck cancer | Details |
| Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase Ⅰ | Zensun | Solid tumours | Details |
| Tesevatinib | EXEL-7647; KD-019; KD-020; XL-647,KD019,EXEL7647,KD020,XL647 | Phase Ⅲ | Exelixis, Kadmon | Non small cell lung cancer (NSCLC), Autosomal dominant polycystic kidney disease (ADPKD) | Details |
| Trastuzumab biosimilar (United BioPharma) | UB-921 | Phase Ⅰ | United BioPharma | Breast cancer | Details |
| Recombinant anti-HER2 humanized monoclonal antibody-DM1 (Qilu Pharmaceutical) | Phase Ⅰ | Qilu Pharmaceutical | Breast cancer | Details | |
| TPIV-100 (TapImmune) | TPIV-100 | Phase Ⅱ | Mayo Clinic, TapImmune | Breast cancer | Details |
| CIDeCAR | Phase Ⅰ | Bellicum, National Cancer Institute | Solid tumours, Osteosarcoma | Details | |
| IBPM002BZ (Inbiopro Solutions) | IBPM-002BZ | Phase Not Specified | Inbiopro Solutions | Small cell lung cancer (SCLC), Renal cell carcinoma, Colorectal cancer | Details |
| MP-0274 | CME-114; SPA-28; MP-0274; CME-119; CME-118; CME-115; DARPin-41 | Phase Ⅰ | Molecular Partners | Solid tumours | Details |
| XMT-1522 | TAK-522; XMT-1522,TAK 522 | Phase Ⅰ | Mersana Therapeutics, Adimab, Takeda | Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer | Details |
| anti-HER2 ADC (Pfizer) | PF-06804103 | Phase Ⅰ | Pfizer | Solid tumours | Details |
| Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) | Phase Ⅰ | Seattle Children's Research Institute | Central nervous system tumors | Details | |
| 99m-Tc labeled anti-HER2 single domain antibody (NanoMab) | 99mTc-NM-02 | Phase Ⅰ | NanoMab Technology Ltd | Breast cancer | Details |
| HER2 cancer vaccine (BioLife Science) | IMU-131; PEV-6A; PEV-6,IMU 131; PEV 6A; PEV 6,IMU131; PEV6A; PEV6 | Phase Ⅱ | Pevion Biotech, Imugene, Mymetics Corporation | Gastric cancer, Esophagus cancer, Breast cancer | Details |
| BAT-8001 | BAT-8001 | Phase Ⅲ | Bio-Thera Solutions | Solid tumours, Metastatic breast cancer | Details |
| ARX-788 | ARX-788 | Phase Ⅰ | Ambrx, Zhejiang Medicine | Solid tumours | Details |
| PB-357 | PB-357 | Phase Ⅰ | Pfizer | Solid tumours | Details |
| ACE-1702 | ACE-1702 | Phase Ⅰ | Acepodia | Solid tumours | Details |
| Recombinant anti-HER2 subdomain II humanized monoclonal antibody (Livzon Group) | LZM-005 | Phase Ⅰ | Livzon Group Livzon Pharmaceutical Factory | HER2-positive metastatic breast cancer, HER2-positive breast cancer | Details |
| HLX-22 | AC-101; HLX-22 | Phase Ⅰ | AbClon, Shanghai Henlius Biotech | Gastric cancer, Breast cancer | Details |
| 重组人源化抗HER2单克隆抗体（喜康生物） | IND Filing | JHL Biotech | Solid tumours | Details | |
| IBPM003TZ (Inbiopro Solutions) | IBPM-003TZ | Phase Not Specified | Inbiopro Solutions | Breast cancer | Details |
| HER-2 peptide-expressing DNA vaccine (Karolinska Institute) | Phase Ⅰ | Karolinska Institutet (KI) | Cancer | Details | |
| tgDCC-E1A gene therapy (Targeted Genetics) | Phase Ⅱ | Targeted Genetics | Breast cancer, Ovarian cancer, Head and neck cancer | Details | |
| MVA-BN-HER2 | PX-1032; PX-103.2 | Phase Ⅱ | Pharmexa, Bavarian Nordic | Breast cancer | Details |
| AU-105 | AU-105 | Phase Ⅱ | Aurora BioPharma | Glioblastoma multiforme | Details |
| Trastuzumab biosimilar (EirGenix) | EG-12014 | Phase Ⅲ | EirGenix | Breast cancer | Details |
| DZD-9008 | DZD-9008,DZD9008 | Phase Ⅱ | Dizal (Jiangsu) Pharmaceutical | Advanced non small cell lung cancer | Details |
| BDTX-189 | BDTX-189,BDTX189 | Phase Ⅱ | Black Diamond Therapeutics | Solid tumours | Details |
| SHR-1309 | SHR-1309,SHR1309 | Phase Ⅰ | Jiangsu Hengrui Medicine | HER2-positive metastatic breast cancer | Details |
| PKI-166 | CGP-75166; PKI-166; PKI-75166 | Phase Ⅱ | Novartis | Solid tumours | Details |
| Sirotinib Maleate | XZP-5491,XZP5491 | Phase Ⅰ | XuanZhu Pharma | Esophageal squamous cell carcinoma, Non small cell lung cancer (NSCLC), Gastric cancer | Details |
| Trastuzumab biosimilar | CMAB-809 | Phase Ⅰ | Taizhou Mabtech | Gastric cancer, Breast cancer | Details |
| Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) | Phase Ⅰ | Shenzhen Main Luck Pharmaceuticals | Breast cancer | Details | |
| BVAC-B vaccine (Cellid) | BVAC-B | Phase Ⅰ | Cellid Company | Gastric cancer | Details |
| M-802 | M-802,M802; M 802 | Phase Ⅰ | YZY Bio | Gastric cancer, HER2-positive breast cancer | Details |
| Recombinant anti-HER2 humanized monoclonal antibody complex | B-002,B002 | Phase Ⅰ | Shanghai Pharma | HER2-positive breast cancer | Details |
| Sym-013 | Sym-013 | Phase Ⅱ | Symphogen | Cancer | Details |
| Recombinant humanized anti-EGFR monoclonal antibody (Hisun Pharm/Mabworks Biotech) | HS627 | Phase Ⅰ | Beijing Mabworks Biotech, Hisun Pharm | Breast cancer | Details |
| Trastuzumab biosimilar (Shanghai CP Guojian) | CMAB-302 | BLA Filing | Shanghai CP Guojian | Breast cancer | Details |
| 212 Pb-trastuzumab | Phase Ⅰ | Areva Pharmaceuticals, University of Alabama at Birmingham, University of Cincinnati | Metastatic cancer | Details | |
| Trastuzumab biosimilar (Gedeon Richter) | Preclinical | Gedeon Richter, STADA Arzneimittel | Gastric cancer, Breast cancer | Details | |
| Pertuzumab biosimilar(SL Pharma/Combio) | Phase Ⅰ | Combio, Beijing ShuangLu Pharmaceutical | Breast cancer | Details | |
| Her-2 vaccine (University of Alabama/Galenica Pharmaceuticals) | Phase Ⅰ | University of Alabama at Birmingham, Adjuvantys | Breast cancer | Details | |
| Trastuzumab biosimilar (BioXpress Therapeutics) | BX-2318 | Phase Not Specified | BioXpress Therapeutics SA | Breast cancer | Details |
| Trastuzumab biosimilar (Alteogen) | ALT-02; ALT-L2; ALT-LS2 | Phase Ⅰ | Alteogen, Cristalia, Qilu Pharmaceutical | Breast cancer, Metastatic gastric carcinoma, HER2-positive metastatic breast cancer, Gastroesophageal junction adenocarcinoma | Details |
| Recombinant HER2 humanized monoclonal antibody -DM1 conjugate (Shanghai CP Guojian Pharmaceutical) | IND Filing | Shanghai CP Guojian | Unspecified | Details | |
| Gancotamab (Merrimack) | MM-302 | Phase Ⅲ | Merrimack, Baxter, Johnson & Johnson | Breast cancer | Details |
| MDX H210 | Phase Ⅱ | Medarex | Prostate cancer, Breast cancer | Details | |
| HER2/neu peptide vaccine (Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium) | Phase Ⅱ | Fred Hutchinson/University of Washington Cancer Consortium | HER2-positive breast cancer | Details | |
| Prolanta(Oncolix) | Phase Ⅰ | Oncolix | Fallopian tube cancer, Prostate cancer, Breast cancer, Solid tumours, Peritoneum cancer, Ovarian cancer | Details | |
| IBI315 | IBI-315; IBI315 | Phase Ⅰ | Innovent Biologics, Hanmi | Cancer | Details |
| HER2-antigen specific cancer vaccine | HER2-ASCI | Phase Ⅱ | GlaxoSmithKline | Breast cancer | Details |
| IDM-1 | IDM-1; MAK/IDM-1; MDX-210/MAK cells | Phase Ⅲ | Takeda | Ovarian cancer | Details |
| Lapatinib/Pazopanib | Phase Ⅲ | GlaxoSmithKline | Renal cell carcinoma | Details | |
| MM-111 | MM-111 | Phase Ⅱ | Merrimack | Gastric cancer, Esophagus cancer, Breast cancer, Solid tumours | Details |
| Canertinib Dihydrochloride | CI-1033; PD-0183805; PD-183805 ,CI1033, PD 0183805,PD 183805 | Phase Ⅱ | Pfizer | Non small cell lung cancer (NSCLC), Breast cancer, Ovarian cancer, Head and neck cancer | Details |
| Cipatinib Tosylate | SHR-1086 | Phase Ⅰ | Hansoh Pharma, Shanghai Pharma | Breast cancer, Lung cancer | Details |
| BMS-986186 | BMS-986186; FS-102 | Phase Ⅰ | F-star, Bristol-Myers Squibb | Gastric cancer, Breast cancer, Solid tumours | Details |
| HER2/neu cancer vaccine (University of Washington/Corixa/GSK) | Phase Ⅱ | University of Washington, GlaxoSmithKline | Breast cancer | Details | |
| AP-32788 | TAK-788; AP-32788 | Phase Ⅲ | Takeda, Millennium Pharmaceutical, Ariad | Non small cell lung cancer (NSCLC) | Details |
| ZW-49 | ZW-49 | Phase Ⅰ | Zymeworks, BeiGene | Gastric cancer, Breast cancer, Solid tumours | Details |
| Zenocutuzumab | MCLA-128 | Phase Ⅱ | Merus | Non small cell lung cancer (NSCLC), Gastric cancer, Solid tumours, Metastatic breast cancer, Ovarian cancer | Details |
| Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) | Phase Ⅰ | Beijing Mabworks Biotech, Hisun Pharm | Breast cancer | Details | |
| Pertuzumab biosimilar (CTTQ) | Phase Ⅰ | Chiatai Tianqing (CTTQ) | HER2-positive metastatic breast cancer | Details | |
| Autologous-HER2-specific-T-cells | Autologous-HER2-specific-T-cells | Phase Ⅰ | Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System | Sarcoma | Details |
| TGFBeta-resistant-HER2-EBV-CTLs | TGFBeta-resistant-HER2-EBV-CTLs | Phase Ⅰ | Baylor College of Medicine, Methodist Hospital System | Malignancies | Details |
| TAS-0728 | TAS-0728; TPC-107 | Phase Ⅱ | Taiho Pharma | Solid tumours | Details |
| Tarloxotinib Bromide | TH-4000; PR-610; SN-33999 | Phase Ⅱ | Threshold | Non small cell lung cancer (NSCLC) | Details |
| BCD-147 | BCD-147 | Phase Ⅰ | Biocad | Unspecified | Details |
| VB-7756 (Sesen Bio) | VB-7756 | Preclinical | Viventia Biotech, Sesen Bio | Cancer | Details |
| Bispecific monoclonal antibody 2B1 | Phase Ⅰ | Chiron | Cancer | Details | |
| Epertinib | S-222611,S222611 | Phase Ⅱ | Shionogi | Solid tumours | Details |
| MBS-301 | MBS-301 | Phase Ⅰ | Beijing Mabworks Biotech | Gastric cancer, Breast cancer, Solid tumours | Details |
| MB-103 | MB-103 | Phase Ⅰ | City of Hope National Medical Center, Mustang Bio | Glioblastoma, Brain metastases | Details |
| Breast cancer vaccine HER-2/neu (GlaxoSmithKline) | Phase Ⅱ | GlaxoSmithKline | Breast cancer | Details | |
| HS-10182 | HS-10182,HS10182 | Phase Ⅰ | Hansoh Pharma | Solid tumours | Details |
| MX-402 | MX-402,MX 402,MX402 | Phase Ⅰ | MedVax Technologies | Gastric cancer | Details |
| Lapuleucel-T | APC-8024; BA-7072; DN-2402 | Phase Ⅱ | Dendreon Corporation | Urogenital cancer | Details |
| ZW-25 | ZW-25 | Phase Ⅱ | Zymeworks, BeiGene | Fallopian tube cancer, Gllbladder cancer, Gastric cancer, Esophagus cancer, Breast cancer, Colorectal cancer, Ovarian cancer, Cervical carcinoma, Biliary cancer | Details |
| Pertuzumab biosimilar (NeuClone) | Preclinical | NeuClone | Breast cancer, HER2-positive metastatic breast cancer | Details | |
| Trastuzumab biosimilar (Dong-A ST/Meiji Seika Pharma) | DA-3111; DMB-3111 | Phase Ⅰ | Dong-A Pharmaceutical, Meiji Seika Pharma | Gastric cancer, Breast cancer | Details |
| Poziotinib | HM-78136; HM-78136B; NOV1201; NOV-120101 | Phase Ⅱ | Hanmi, Luye Pharma, Spectrum Pharmaceuticals | Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Lung cancer, Head and neck cancer | Details |
| Trastuzumab conjugate (BioIntegrator) | BI-CON-02 | Phase Ⅰ | BioIntegrator | Breast cancer | Details |
| HER.CAR-CMV-specific-CTLs | HER.CAR-CMV-specific-CTLs | Phase Ⅰ | Baylor College of Medicine, Methodist Hospital System, Texas Children's Hospital | Glioblastoma multiforme | Details |
| Trastuzumab biosimilar (Shanghai Henlius Biotech) | HLX-02 | BLA Filing | Shanghai Henlius Biotech, Accord Healthcare | Breast cancer | Details |
| Trastuzumab biosimilar (Harbin Pharmaceutical Group) | IND Filing | Harbin Pharmaceutical Group | Breast cancer | Details | |
| GP2 peptide vaccine (Cancer InSight) | Phase Ⅰ | Cancer Insight | Breast cancer | Details | |
| MT-5111 | MT-5111 | Phase Ⅰ | Molecular Templates | Solid tumours | Details |
| Disitamab Vedotin (Yantai Rongchang Biological Engineering) | RC48-ADC; RC-48; RC-48-ADC | Phase Ⅱ | Yantai Rongchang Biological Engineering, Remegen | Gastric cancer, Urothelial cancer, HER2-positive metastatic breast cancer | Details |
| Recombinant humanized anti-HER2 antibody (Hisun Pharma) | Phase Ⅲ | Hisun Pharm | HER2-positive metastatic breast cancer | Details | |
| MDX-210 | MDX-210 | Phase Ⅱ | Takeda | Prostate cancer, Breast cancer, Colorectal cancer, Renal carcinoma | Details |
| CP-347589 | CP-347589 | Phase Not Specified | Pfizer | Cancer | Details |
| HER-2/Neu pulsed DC1 vaccine (University of Pennsylvania) | Phase Ⅱ | University of Pennsylvania, National Cancer Institute | Breast cancer | Details |
This web search service is supported by Google Inc.
A-Z
